BioSpace News Archive

Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced data updates from two phase 1/2a trials with AFM24, the company’s tetravalent, bispecific innate cell engager, in patients with solid tumors.

Amarin Corporation plc highlighted key data presented at the American Heart Association 2022 Scientific Sessions relevant to VASCEPA®/VAZKEPA and patient care.

ReWalk Robotics Ltd., a leading manufacturer of robotic medical technology for people with lower extremity disabilities, announced its financial results for the three and nine months ended September 30, 2022.

Oyster Point Pharma, Inc., announced that it has entered into a definitive agreement under which Viatris Inc., a global healthcare company, would acquire Oyster Point Pharma, a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases.

Inhibikase Therapeutics, Inc. announced that the Company was informed via e-mail communication that the U.S. FDA has reviewed its Investigational New Drug application for IkT-148009 for the treatment of Multiple Systems Atrophy and has issued a Clinical Hold on the IkT-148009 201 program in Parkinson’s disease and the use of IkT-148009 in MSA.

SeekIn Inc announced the results of the pan-cancer/pan-indication treatment response monitoring test, SeekInClarity®, which were presented at the AMP 2022 Annual Meeting & Expo in Phoenix, Arizona, United States.

Renibus Therapeutics, Inc., (“Renibus”) today announced that interim Phase 2 data for RBT-1 (stannous protoporphyrin/iron sucrose) were presented during an oral session at the American Heart Association (AHA) Scientific Sessions 2022 meeting, being held November 5-7, 2022, in Chicago, Illinois.

OncoHost, a global leader in next-generation precision oncology for improved personalized cancer therapy, has developed a novel predictive model for clinical benefit of immune checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients.

Viatris Inc. announced that it intends to create an ophthalmology franchise by acquiring Oyster Point Pharma and Famy Life Sciences and that it will provide a strategic update on its February 2022 Investor Event in a conference call and live webcast today at 8:30 a.m. ET.

Seal Rock Therapeutics, Inc. today announced promising clinical and preclinical results for SRT-015, a second-generation apoptosis signal-regulating kinase (ASK1) inhibitor for treatment of alcoholic hepatitis and other liver diseases during an oral and poster presentation at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD).